Evidence map›Paper›PMID 40988940›Full record

ArticleBioactive materials2025

Adaptive bioactivable nanosystems for synergistic myocardial infarction therapy using traditional pharmaceutics.

Shuai Mao, Yubin Liang, Zikang Chen, Lei Wang, Quanfu Chen, Zhuting Fang, Qifan Zheng, Wen Ma, Hanping Zhang, Zhiqiang Yu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Biointegrated Battery-Based Electroceuticals.Advanced materials (Deerfield Beach, Fla.) · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shuai MaoState KeyLaboratory ofTraditional Chinese MedicineSyndrome/Department of Critical Care Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, China.
Yubin LiangState KeyLaboratory ofTraditional Chinese MedicineSyndrome/Department of Critical Care Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, China.
Zikang ChenDepartment of Oncology and Vascuar Interventonal Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
Lei WangState KeyLaboratory ofTraditional Chinese MedicineSyndrome/Department of Critical Care Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, China.
Quanfu ChenGuangzhou Hospital of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510130, China.
Zhuting FangDepartment of Oncology and Vascuar Interventonal Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
Qifan ZhengState KeyLaboratory ofTraditional Chinese MedicineSyndrome/Department of Critical Care Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, China.
Wen MaStrait Laboratory of Flexible Electronics (SLoFE), Fujian Key Laboratory of Flexible Electronics, Strait Institute of Flexible Electronics (SIFE, Future Technologies), Fujian Normal University, Fuzhou 350117, China.
Hanping ZhangDepartment of Cardiology, Guangzhou Development District Hospital, Guangzhou, 510730, China.
Zhiqiang YuDepartment of Laboratory Medicine, Dongguan Institute of Clinical Cancer Research, The Tenth Affiliated Hospital (Dongguan People's Hospital), Southern Medical University, Dongguan, 523058, China.
Ling YuState KeyLaboratory ofTraditional Chinese MedicineSyndrome/Department of Critical Care Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure resulting from myocardial infarction (MI) is a leading global health concern. Current revascularization therapies cannot fully restore the infarcted myocardium or prevent maladaptive ventricular remodeling. Traditional Chinese medicine with its multitarget regulation and favorable biosafety shows a promising therapeutic potential. Tanshinone IIA (TIIA) and formononetin (FM), two bioactive compounds derived from

Indexed as

AngiogenicAnti-inflammatoryBioactivableMyocardial infarctionSize-transformable

Identifiers

PMID40988940
PMCPMC12451291

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.